Mirum: Livmarli authorized in Canada for cholestatic pruritus in ALGS patients

Mirum Pharmaceuticals announced that LIVMARLI or, maralixibat oral solution, has been authorized by Health Canada for the treatment of cholestatic pruritus in patients with Alagille syndrome or ALGS. “We are thrilled that patients in Canada will now have access to LIVMARLI as we have seen the powerful impact it can have on people living with life-altering pruritus ALGS is a rare genetic disorder caused by abnormalities in bile ducts that can lead to progressive liver disease. Malformed or reduced bile ducts cause cholestasis, the accumulation of bile acids in the liver, which leads to inflammation and liver injury, and prevents the liver from working properly. Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.